Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF11 | P52732 | 1/20 | 0.38 |
| ▸ | CETP | P11597 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15146059 | 0.80 | KCNN4 (0.35) | KIF11CETP | |
| SCHEMBL15142667 | 0.80 | KCNN4 (0.35) | KIF11CETP | |
| SCHEMBL15904458 | 0.77 | AAK1 (0.30) | — | |
| SCHEMBL15903135 | 0.77 | MAP2K1 (0.31) | — | |
| SCHEMBL15903516 | 0.75 | PTPN7 (0.33) | — | |
| SCHEMBL15990930 | 0.75 | BACE1 (0.33) | CETP | |
| Hydrochloric Acid SCHEMBL15990924 | 0.74 | PTPN7 (0.32) | — | |
| SCHEMBL15903097 | 0.72 | CETP (0.33) | CETP | |
| SCHEMBL15909916 | 0.72 | CETP (0.33) | CETP | |
| SCHEMBL16348230 | 0.71 | KIF11 (0.45) | KIF11SMN1; SMN2CYP11B1CYP11B2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150376172-A1 | FLUORO-[1,3]OXAZINES AS BACE1 INHIBITORS | WOLTERING THOMAS (US) | 2015-12-31 | — | — | US | disclosed |
| EP-2948446-A1 | FLUORO-[1,3]OXAZINES AS BACE1 INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2015-12-02 | — | — | EP | disclosed |
| WO-2014114532-A1 | FLUORO-[1,3]OXAZINES AS BACE1 INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2014-07-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150376172-A1 | FLUORO-[1,3]OXAZINES AS BACE1 INHIBITORS | BACE1, BACE2, PSEN1 | KIF11 4020/4885CETP 1179/4885SMN1; SMN2 685/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.